Question special

Thanks to Dr. Solomon for answering the first question about the conception of the study - he let us know that the FDA required that Pfizer study this question due to the concern about CV safety. As a follow-up question, can one of the authors tell us more about this academic-industry collaboration? How did Pfizer decide to partner with your group, and what role did they have in the trial design?